<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.2d1 20170631//EN" "JATS-journalpublishing1.dtd">
      <Volume-Issue>Volume 12, Issue 4</Volume-Issue>
      <Season>October- December, 2020</Season>
      <ArticleTitle>Mini-review on impact of known drug-drug interactions in cancer patients</ArticleTitle>
      <Abstract>When a patient concomitantly uses two or more drugs, a drug-drug interaction (DDI) can possibly occur, potentially leading to an increased or decreased clinical effect of a given treatment. Cancer patients are at high risk of such interactions because they commonly receive multiple medications. Moreover, most cancer patients are elderly and require additional medications for comorbidities. Majorly, drugs with narrow therapeutics index cause more potential DDI. Severity of the interaction shows individual variability because of genetic polymorphism. Therefore, it is essential to properly detect DDI. The aim of this article is to study the different DDIs reviewed by several articles and a cohort of cancer outpatients undergoing multiple treatments.</Abstract>
      <Keywords>Drug-drug interaction, Narrow therapeutic index, New drug-dug interaction, Over-the-counter</Keywords>
        <Abstract>https://isfcppharmaspire.com/ubijournal-v1copy/journals/abstract.php?article_id=13805&amp;title=Mini-review on impact of known drug-drug interactions in cancer patients</Abstract>
        <References>1. Moghaddas A, Adib-Majlesi M, Sabzghabaee AM, Hajigholami A, RiechelmannR. Potential drug-drug Interactions in hospitalized cancer patients: A report from the Middle-East. J Oncol Pharm Pract 2020;17:1078155220910209.&#13;
2. Assiri A, Noor A. A computational approach to predict multi-pathway drugdrug interactions: A case study of irinotecan, a colon cancer medication. Saudi Pharm J 2020;29:17.&#13;
3. Roberts AG, Gibbs ME. Mechanisms and the clinical relevance of complex drug-drug interactions. Clin Pharmacol 2018;10:123-34.&#13;
4. Ussai S, Petelin R, Giordano A, Malinconico M, Cirillo D, Pentimalli F. A pilot study on the impact of known drug-drug interactions in cancer patients. J Exp Clin Cancer Res 2015;34:89.&#13;
5. Kaur V, Kaur K, Singh A. Development and characterization of probiotic loaded suppositories for cervical cancer management. Development 2020;1:48-53.&#13;
6. O’brien SN, Blijlevens N, Mahfouz TH, Anaissie EJ. Infections in patients with hematological cancer: Recent developments. Hematology 2003;1:438-72.&#13;
7. Lorberbaum T, Sampson KJ, Woosley RL, Kass RS, Tatonetti NP. An integrative data science pipeline to identify novel drug interactions that prolong the QT interval. Drug Saf 2016;39:433-41.&#13;
8. Singh A, Kaur K, Mandal UK, Narang RK. Nanoparticles as budding trends in colon drug delivery for the management of ulcerative colitis. Curr Nanomed 2020;10:225-47.</References>